Antiangiogenesis Drugs--Fitz Flashcards
Bevacizumab
MOA: humanized monoclonal antibody against VEGF
TU: metastatic colorectal cancer w/ 5-FU, lung cancer, macular degeneration
Tox: GI performation*, wound dehiscence, hemoptysis, worsen coronary artery disease
Sorafinib
MOA: VEGF and PDGF TK antagonists
TU: renal cell carcinoma
PK: CYP3A4 metabolism
Tox: CHF, MI, teratogenic, HTN, hemorrhage
Pazopanib
MOA: VEGF and PDGF TK antagonist
TU: renal cell carcinoma
PK: CYP3A4 metabolism, high plasma protein binding, PO
Tox: CHF, MI, teratogenic, hepatotoxicity
Sunitimib
MOA: VEGF and PDGF TK antagonist
TU: renal cell carcinoma
PK: CYP3A4 metabolism, high protein binding, PO
Tox: CHF, MI, teratogenic, hand-foot syndrome
Everolimus
MOA: mTOR inhibition (anti-VEGF, G1/S transition block)
PK: CYP3A4 metabolism
Resistance: MDR
Tox: lymphoma, renal arterial and venous thrombosis
Tamisorolimus
MOA: mTOR inhibition (anti-VEGF, G1/S transition block)
PK: CYP3A4 metabolism
Resistance: MDR
Tox: lymphoma, renal arterial and venous thrombosis
Lenalidomide, pamalidomide, thalidomide
MOA: suppress immune and inflammatory response, antiangiogenic, Th2 > Th1 activation
TU: MM
PK: PO, renal excretion
Tox: peripheral neuropathy, DVT (warfarin indicated in MM), severe teratogenic effects (phocomelia)